Induction of ER (endoplasmic reticulum) stress-mediated apoptosis in cancer cells represents an alternative approach for cancer therapy. Whether FGF-2 (fibroblast growth factor 2)-induced survival signals may interact with ER stress signalling in cancer cells remains elusive. In the present study, we showed that pretreatment with FGF-2 decreased the inhibition of DNA synthesis and induction of apoptosis by two different ER stress inducers, TM (tunicamycin) and TG (thapsigargin), in both human hepatoblastoma HepG2 cells and breast cancer MCF-7 cells. Pretreatment with FGF-2 prevented ER stress-mediated apoptosis by decreasing ER stress-induced CHOP [C/EBP (CCAAT/enhancer-binding protein)-homologous protein] expression. We further demonstrated that pretreatment with FGF-2 mediated the decrease in TM-induced CHOP expression and apoptosis through ERK1/2 (extracellular-signalregulated kinases 1 and 2) pathway. Finally, we demonstrated that FGF-2 promoted proteasome-mediated degradation of Nck (non-catalytic region of tyrosine kinase adaptor protein), an SH (Src homology) 2/SH3-containing adaptor protein. Whereas overexpression of Nck1 decreased FGF-2-induced ERK1/2 phosphorylation to inhibit the effect of FGF-2 on TM-induced CHOP expression and apoptosis, a decrease in Nck expression prevented TM-induced CHOP expression and apoptosis. Taken together, the findings of the present study provide the first evidence that Nck plays a pivotal role in integrating FGF-2 and ER stress signals to counteract the ER stress deleterious effect on cancer cell survival.
INTRODUCTION
The ER (endoplasmic reticulum), the first compartment of the secretory pathway, mainly functions in proper secretory protein folding and transport. The disruption of ER homoeostasis by a number of cellular stresses, such as perturbed calcium homoeostasis, redox status, acute secretory protein synthesis rates, altered N-glycosylation and cholesterol overload, leads to an evolutionarily conserved cell response (unfolded protein response or ER stress) [1, 2] . The primary biological goal of the ER stress response is to re-establish the normal function of the ER. However, ER stress may lead to apoptosis when ER dysfunction is severe or prolonged [3] . ER stress is mediated by three signalling components, such as PERK [PKR (double-stranded-RNA-dependent protein kinase)-like ER kinase], IRE1α (inositolrequiring enzyme-1α) and ATF6α (activating transcription factor 6α) [4] . The three arms of ER stress signalling are capable of inducing the transcription of GADD153 (growtharrest and DNA-damage-inducible protein 153)/CHOP [C/EBP (CCAAT/enhancer-binding protein)-homologous protein] [5] . ER stress is required to maintain malignancy and therapy resistance in cancer cells [6] [7] [8] . Following the initiation of malignancy, poor vascularization of the tumour mass leads to nutrient starvation, hypoxia and alterations in the redox environment which are strong inducers of ER stress [8, 9] . Furthermore, the increased rate of protein folding and assembly in the ER to satisfy higher rates of cancer cell growth induces ER stress [10, 11] . Thus the induction of ER stress-mediated apoptosis in cancer cells represents an alternative approach in cancer therapy.
The cross-talk between ER stress signalling and other signalling pathways has been shown previously. For instance the interaction between PI3K (phosphoinositide 3-kinase) and XBP1 (X-box-binding protein 1) is important for XBP1 nuclear translocation [12, 13] . The dual-specificity phosphatase MKP1/DUSP1 functions downstream of IRE1α [3, [14] [15] [16] . ER stress is also observed in TLR (Toll-like receptor) signalling [17] . However, the underlying mechanism remains unknown and the SH (Src homology) 2/SH3-containing adaptor proteins probably have an important function in the cross-talk. Thus CRK, the adaptor protein that is known for its function in couplingactivated receptors in the plasma membrane with downstream effectors [18] , has been identified as a pro-apoptotic ER stress transducer [19] . Non-catalytic region of tyrosine kinase adaptor protein (Nck), another adaptor protein, is involved in transducing signals from RTKs (receptor tyrosine kinases) to downstream targets and in regulating ER stress signals downstream of either PERK [20, 21] or IRE1α [22, 23] .
FGF-2 (fibroblast growth factor 2) promotes cancer cell proliferation and survival by binding with RTKs. The FGF receptor, in turn, activates ERK1/2 (extracellular-signal-regulated Abbreviations used: CHOP, C/EBP (CCAAT/enhancer-binding protein)-homologous protein; DMEM, Dulbecco's modified Eagle's medium; eIF2α, eukaryotic initiation factor 2α; ER, endoplasmic reticulum; ERK1/2, extracellular-signal-regulated kinases 1 and 2; FBS, fetal bovine serum; FGF-2, fibroblast growth factor 2; GADD153, growth-arrest and DNA-damage-inducible protein 153; HRP, horseradish peroxidase; IGF-I, insulin-like growth factor 1; IRE1α, inositol-requiring enzyme-1α; NC, nitrocellulose; PARP, poly(ADP-ribose) polymerase; PERK, PKR (double-stranded-RNA-dependent protein kinase)-like endoplasmic reticulum kinase; qRT-PCR, quantitative real-time PCR; RTK, receptor tyrosine kinase; SH, Src homology; siRNA, small interfering RNA; TBST, Tris-buffered saline (TBS) and 0.1 % Tween 20; TG, thapsigargin; TLR, Toll-like receptor; TM, tunicamycin; WT, wild-type; XBP1, X-box-binding protein 1.
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kinases 1 and 2) [24] [25] [26] . We demonstrated previously that Nck contributes to the FGF-2-mediated cancer cell survival [26] . In the present study, we focus on the function of FGF-2 on ER stress. We demonstrate that FGF-2 prevents cancer cells from ER stress-induced apoptosis via enhancing proteasome-mediated Nck degradation. The findings of the present study provide new insight into the control of ER stress-mediated growth and apoptosis of cancer cells.
EXPERIMENTAL

Materials
TM (tunicamycin), TG (thapsigargin) and MG-132 (the proteasome inhibitor carbobenzoxy-L-leucyl-L-leucyl-leucinal) were purchased from Calbiochem. FGF-2 was purchased from Sigma. Anti-ERK1/2, anti-pERK1/2, anti-eIF2α (eukaryotic initiation factor 2α), anti-peIF2α-Ser 51 , anti-β-actin, anti-PARP [poly(ADP-ribose) polymerase] and antiNck1 (15B9) antibodies, HRP (horseradish peroxidase)-conjugated goat anti-rabbit secondary antibodies, HRP-conjugated goat anti-mouse secondary antibodies, ERK1/2 siRNA (small interfering RNA) and PD98059 for Western blot analysis were purchased from Cell Signaling Technology. Anti-CHOP antibody, CHOP siRNA and Nck siRNA were purchased from Santa Cruz Biotechnology. FBS (fetal bovine serum), the culture medium and other solutions used for the cell culture were purchased from Invitrogen.
Cell culture
HepG2 and MCF-7 cells (A.T.C.C.; Manassas, VA, U.S.A.) were maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % FBS, 100 units/ml penicillin G and 100 units/ml streptomycin in 5 % CO 2 .
Western blot analysis
Cell lysates from the cultures were ultrasonicated three times with 400 Hz out power, 3 s on and 3 s off, and the protein concentration was determined using Bradford reagent according to the manufacturer's instructions (Bio-Rad Laboratories). Equal protein amounts were resolved by SDS/PAGE on either 12 % or 10 % gels and transferred on to NC (nitrocellulose) membranes (Millipore), which were then blocked with 5 % (w/v) non-fat dried skimmed milk powder in TBST [TBS (Tris-buffered saline) and 0.1 % Tween 20] for 2-4 h. The NC membranes were incubated with primary antibodies overnight at 4
• C, extensively washed with TBST, and incubated for 1-2 h with HRP-conjugated goat anti-rabbit secondary antibodies or HRP-conjugated goat anti-mouse secondary antibodies. After the membranes were extensively washed with TBST, immunoreactive bands were revealed using the Supersignal ELISA FEMTO maximum sensitivity substrate (Pierce) and visualized using X-ray films. The density of the immunoreactive bands was determined using the ImageJ software (NIH). All of the bands were normalized to percentages of the control values.
DNA synthesis assays
Cells were seeded into 24-well culture plates (40 000 cells/well) and grown in DMEM with 10 % FBS overnight. The medium was then removed and fresh DMEM without 10 % FBS was added for 8-12 h, before the treatment with FGF-2 and/or TM was performed for another 24 h. [ 3 H]Thymidine (0.5 μl/well) was added into the medium for the final 4 h of incubation.
[ 3 H]Thymidine incorporation was determined after the cells were fixed with 10 % ice-cold trichloroacetic acid and lysed with 0.3 M NaOH. The incorporated radioactivity was counted via liquid scintillation in a MicroBeta counter (PerkinElmer).
Quantification of apoptotic cells
After the cultures were treated accordingly, the cells were fixed with 4 % paraformaldehyde (30 min), gently rinsed with PBS and stained with propidium iodide (1 mg/ml). The cells were examined via fluorescence microscopy and scored as apoptotic if the cells displayed a condensed or fragmented nucleus. The treated cells were evaluated independently by counting 400-600 cells to determine the percentage of apoptotic cells in each well. The datasets shown were the average of at least three separate experiments.
Nck mutant constructs
Human Nck1 mutants were produced from pcDNA3.1Myc-Nck1 plasmid by using the QuikChange ® site-directed mutagenesis kit according to the manufacturer's protocol (Stratagene). The Nck1 K178A mutant was built using two mutagenic primers: forward, 5 -CTCTGTCAGAGGCATTAGCAGCAG-3 ; and reverse, 5 -CTGCTGCTAATGCCTCTGACAGAG-3 . The Nck1 K369A mutant was built using two mutagenic primers: forward, 5 -GAACAAGGAGAAGCATTATATCTTG-3 ; and reverse, 5 -CAAGATATAATGCTTCTCCTTGTTC-3 .
Transfection
Cells were plated at a density of 2×10 5 cells in plates (diameter = 35 mm). After 24 h, the cells were transfected with pcDNA3.0-Nck1 or siRNA (ERK, Nck and CHOP), control pcDNA3.0 plasmids or siRNA controls by using Lipofectamine TM 2000 (Invitrogen) as described previously [3] . After 24 h, the transfected cells were exposed to G418 (also known as Geneticin) for the selection and left untreated or treated with 10 ng/ml FGF-2 and 10 μg/ml TM (or 2 μM TG).
Immunoprecipitation
Cells were plated in six-well plates and transfected overnight, as described above. Cells were serum starved in the presence of MG-132 (10 μM) for 4 h, treated with FGF-2 for 4 h at 37
• C, and then lysed. The cell lysates were incubated with primary antibodies overnight at 4
• C, and then incubated with Protein A/G-Sepharose (Sigma) for 4 h at 4
• C. The beads were washed three times and boiled for 10 min. The immunoprecipitates were resolved by SDS/PAGE and analysed by immunoblotting.
qRT-PCR (quantitative real-time PCR) analyses
qRT-PCR analysis was performed by using SYBR Green. HepG2 cells were incubated with and without FGF-2 and TM for the indicated time periods, and then lysed using TRIzol ® (Invitrogen). Total RNA was prepared according to the manufacturer's instructions. The RNA concentration was determined and PCR analysis was performed using the following primers: Nck forward, 5 -GGACATGAAGGGGATTTCC-3 ; and reverse, 5 -CCATG-GTGCTGAATTTACG-3 . The data were normalized using glyceraldehyde-3-phosphate dehydrogenase as a reference gene (forward, 5 -TCGGAGTCAACGGATTTGGTCGT-3 ; and reverse, 5 -TGCCATGGGTGGAATCATATTGGA-3 ).
Figure 1 Pretreatment with FGF-2 attenuates ER stress-mediated inhibition of DNA synthesis and apoptosis in cancer cells
(A) HepG2 cells were pretreated with or without FGF-2 (10 ng/ml) for 6 h, and then exposed to 10 μg/ml TM or 2 μM TG for the next 24 h. HepG2 cells were exposed to DMEM as the control treatment. for three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001.
Statistical analyses
Data are presented as means + − S.D. from three to five independent experiments. Statistical analyses were performed using Student's t test. P < 0.05 was considered statistically significant.
RESULTS
Pretreatment with FGF-2 attenuated ER stress-induced inhibition of DNA synthesis and apoptosis in cancer cells
The excessive demand on the protein-folding capacity of the ER causes irremediable ER stress in various tumours due to their higher rates of growth and proliferation. In the present study, we selected two human cancer cell lines, the hepatoblastoma HepG2 cells and breast cancer MCF-7 cells, to evaluate the role of FGF-2 in ER stress-mediated signalling and apoptosis.
We first determined whether FGF-2 decreased the inhibition of DNA synthesis, when both HepG2 and MCF-7 cells were subjected to ER stress induced by TM (which inhibits N-linked glycosylation) and TG (which inhibits the sarcoplasmic/endoplasmic Ca 2 + -ATPase SERCA2b) ER stresses. Both TM and TG inhibited DNA synthesis of HepG2 cells (Supplementary Figure S1A at http://www.biochemj.org/bj/452/bj4520139add.htm). FGF-2 alone had no effect on DNA synthesis in HepG2 cells (Supplementary Figure S1B) . Similar results were observed in MCF-7 cells (Supplementary Figures S1C and S1D) . Pretreatment with FGF-2 decreased either TM-or TG-inhibited DNA synthesis in HepG2 cells in a dose-dependent manner ( Figure 1A ). To further investigate the effect of FGF-2 on ER stress-mediated apoptosis, HepG2 cells were fixed with paraformaldehyde after the TM and TG treatment for 24 h and stained with propidium iodide. The apoptotic cells were evaluated and quantified. As shown in Figure 1(B) , pretreatment with FGF-2 evidently reduced TM-and TG-induced apoptosis in HepG2 cells. Pretreatment with FGF-2 also blocked the TM-and TG-induced inhibition of DNA synthesis ( Figure 1C ) and apoptosis ( Figure 1D ) in MCF-7 cells.
We further measured whether FGF-2 has an impact on ER stress-mediated apoptosis signalling such as CHOP (also known as DDIT3 and GADD153) expression and PARP cleavage. Both the induction of CHOP expression and PARP cleavage observed on either TM or TG treatment were blocked by pretreatment with FGF-2 in HepG2 cells (Figure 2A) . In MCF-7 cells, pretreatment with FGF-2 also abrogated TM-and TG-induced CHOP expression and PARP cleavage ( Figure 2B ). However, pretreatment with FGF-2 had no effect on the kinetics of TM-induced phosphorylation of eIF2α in both cell lines ( Figure 2C) . To characterize the function of CHOP expression in ER stress-mediated apoptosis, siRNA-mediated CHOP expression silencing was achieved in HepG2 cells. Down-regulation of CHOP expression was correlated with a marked decrease in TM-induced PARP cleavage ( Figure 2D ) and TM-induced apoptosis ( Figure 2E ), confirming the role of CHOP in ER stress-mediated apoptosis. Together, these results showed that pretreatment with FGF-2 attenuated ER stress-mediated apoptosis and signalling in cancer cells. After transfection was performed for 24 h, cells were treated with and without FGF-2, and then exposed to TM for 4 h. ERK1/2, CHOP and PARP were also detected via immunoblot analysis. (E) HepG2 cells were pretreated as described in (C), and then treated with TM for 24 h. Cells were washed, fixed in paraformaldehyde and stained with propidium iodide. Apoptotic cells were counted and quantification was shown. (F) HepG2 cells were transfected with either scrambled siRNA or siRNA ERK1/2. After transfection for 24 h, the cells were treated with TM for 24 h. Apoptotic cells were counted as described in (E). Data are represented as a means + − S.E.M. for three independent experiments. **P < 0.01 and ***P < 0.001.
ERK1/2 signalling contributes to the effect of FGF-2 on ER stress-mediated apoptosis
To explore how pretreatment with FGF-2 antagonizes ER stressmediated apoptosis, we first monitored the activation of ERK1/2 pathways by FGF-2 on TM exposure. In HepG2 cells, TM only induced slight and transient ERK1/2 activation, whereas FGF-2 led to a strong and prolonged ERK1/2 activation in both the absence and presence of TM ( Figures 3A and 3B) . In an attempt to verify whether ERK1/2 was involved in FGF-2-inhibited TMinduced apoptosis, we used both pharmacological and genetic approaches to impair either ERK1/2 activity or its expression, and then monitored the expression of CHOP and PARP cleavage in HepG2 cells. Pretreatment with PD98059, a MEK1 [MAPK (mitogen-activated protein kinase)/ERK kinase] inhibitor, or silencing by siRNA towards ERK1/2, prevented FGF-2-inhibited CHOP expression and PARP cleavage induced by TM ( Figures 3C  and 3D ), suggesting that ERK1/2 activation contributes to FGF-2-mediated alleviation of TM-induced apoptosis. Indeed, the ERK1/2 pathway has been reported to regulate CHOP expression [27, 28] . Finally, both PD98059 treatment and ERK1/2 silencing abrogated the rescue effect of FGF-2 on TM-induced apoptosis in HepG2 cells ( Figures 3E and 3F ), further confirming that ERK1/2 activation contributes to FGF-2-inhibited TM-induced apoptosis.
Pretreatment with FGF-2 inhibited ER stress-mediated apoptosis through a decrease in Nck expression
We next sought to characterize how FGF-2 prevents cells from ER stress-mediated apoptosis via the ERK1/2 pathway. Nck was involved in either FGF-2-mediated downstream signalling [18] or ER stress signalling [20] [21] [22] [23] . To verify the role of Nck in this process, we determined Nck expression in HepG2 cells. TM treatment alone caused a slight increase in Nck protein ( Figure 4A , upper panel) and mRNA expression ( Figure 4A , lower panel). FGF-2 treatment alone decreased Nck protein expression ( Figure 4B ), but had no effect on Nck mRNA expression ( Figure  4C ). Pretreatment with FGF-2 also decreased TM-induced Nck protein expression ( Figure 4B ) and reversed the effect of TM on Nck mRNA expression ( Figure 4C ). To verify the role of FGF-2-decreased Nck expression in ER stress, we first generated HepG2 stable cell lines by overexpressing a Myc-tagged Nck1. In Nck1-overexpressing HepG2 cells, FGF-2 failed to induce the activation of ERK1/2, whereas it did efficiently in mocktransfected cells (HepG2 cells transfected with pcDNA3.0 as a control) ( Figure 4D ). Overexpression of Nck1 decreased FGF-2-inhibited CHOP expression and PARP cleavage induced by TM ( Figure 4E ). Furthermore, overexpression of Nck1 also abrogated FGF-2-inhibited ER stress-mediated apoptosis ( Figure 4F ). We also attenuated Nck expression by siRNA in HepG2 cells. A The overexpressed Nck1 and mock cells were pretreated with and without FGF-2 for 6 h, and then treated with TM for 24 h. Cells were washed, fixed in paraformaldehyde and stained with propidium iodide. Apoptotic cells were counted and quantification is shown. *P < 0.05 and **P < 0.01.
decrease in Nck expression increased FGF-2-induced ERK1/2 phosphorylation ( Figure 5A ). A decrease in Nck expression also attenuated TM-induced CHOP expression and PARP cleavage ( Figure 5B ), and apoptosis ( Figure 5C ). Taken together, the results of the present study show that the maintenance of Nck expression reduced the beneficial effects mediated by FGF-2 on TM-treated cells, suggesting that Nck is an important signal integrator to modulate the balance between FGF-2 signalling and ER stressmediated apoptosis.
FGF-2 enhances proteasome-mediated degradation of Nck
We then tested whether the FGF-2-mediated decrease in Nck protein expression was dependent on the proteasome. The expression of Nck on FGF-2 treatment was monitored in the presence of the proteasome inhibitor MG-132. MG-132 alone had no impact on Nck protein expression ( Figure 6A ). However, pretreatment with MG-132 blocked the FGF-2-induced decrease in Nck protein expression ( Figure 6A ). Pretreatment with MG-132 also led to the appearance of ubiquitinated forms of Nck in FGF-2-stimulated cells ( Figure 6B ), suggesting that FGF-2 induces ubiquitination of Nck. It has been reported that lysine residues in target protein is important for the protein ubiquitination [29] . On the basis of bioinformatic analysis [30] , amino acid residues Lys 178 and Lys 369 of Nck were highlighted to be potential candidate sites for ubiquitination (Supplementary Table S1 at http://www.biochemj.org/bj/452/bj4520139add.htm). To investigate whether both sites are critical for Nck ubiquitination and degradation, we mutated each potential lysine residue into alanine. When HepG2 cells were transfected with these constructs, FGF-2 treatment failed to facilitate degradation of the Nck1 mutant with the K178A substitution ( Figure 6C , upper panel), but still enhanced the degradation of the K369A Nck1 mutant ( Figure 6C , lower panel). As result, when degradation of mutants was blocked by MG-132 in FGF-2-stimulated cells, K178A Nck1 did not show any ubiquitinated forms ( Figure 6D , middle panel), whereas ubiquitinated WT (wild-type) and K369A Nck1 could be readily detected ( Figure 6D , left-and right-hand panels). These data indicate that FGF-2 promoted proteasome-mediated Nck degradation by facilitating ubiquitination at Lys 178 in the Nck protein.
DISCUSSION
In the present study, we have demonstrated that pretreatment with FGF-2 attenuates ER stress-induced apoptosis via the down-regulation of CHOP expression in cancer cells. ER stress signalling has been reported to interact with traditional signalling axes elicited from the plasma membrane [17, 31, 32] . CHOP is considered as a key effector of ER stress-induced apoptosis [33] . Indeed, activation of TLRs enables cells to avoid apoptosis through repressing the expression of CHOP [31] . NGF (nerve growth factor)-mediated pro-survival signals also depend on the decrease in CHOP expression in ER-stressed cells [34] . However, IGF-I (insulin-like growth factor 1) is demonstrated to enhance cell resistance to ER stress via increasing the CHOP expression in MCF-7 cells [32] and protect PC-12 cells from ER stress-induced apoptosis without changing the expression level of CHOP [35] . The different effect on CHOP expression induced by either FGF-2 or IGF-I may be explained by the fact that ER stress induced by different stimuli does not necessarily share the same signalling pathways and needs to be further characterized. It has been shown that the ERK1/2 pathway protects cells from ER stress-induced apoptosis [36] and ERK1/2 has dual roles in regulating CHOP gene expression [37] . We demonstrated previously that FGF-2 promotes cancer cell proliferation and survival through ERK1/2 [24] [25] [26] 38] . In the present study, our data supported the fact that FGF-2-inhbited ER stressinduced apoptosis was also dependent on FGF-2-induced ERK1/2 activation. Furthermore, we identified Nck as a checkpoint to link ER stress-and FGF-2-mediated signalling pathways. Nck acts as a transducer of ER stress, regulating ER stress signals either downstream of PERK or IRE1α. PERK activation is negatively regulated by Nck [20, 21] . Nck interacts with IRE1α to modulate ERK1/2 activation [23] . Nck is also involved in Ras signalling. Nck can directly bind to RasGAP (GTPase-activating protein of Ras) [39] and induce Ras-dependent gene expression [40] . Depletion of Nck leads to reduced ERK activation [41] . FGF-2 mediated cancer cell proliferation via Nck [26] . In the present study, we showed that overexpression of Nck interrupted FGF-2-induced activation of ERK1/2 to decrease the antagonistic effects of FGF-2 on ER stress, and Nck silencing resulted in a similar protective effect by FGF-2 on cells subjected to ER stress, suggesting that the decrease in Nck expression by FGF-2 is important for the antagonistic effect of FGF-2 on ER stress-mediated apoptosis via regulation of ERK1/2. Finally, we demonstrated, for the first time, that FGF-2 decreased Nck protein expression through Nck proteasome-dependent degradation and FGF-2 induced Nck ubiquitination at Lys 178 . Indeed, IGF-I also induces ubiquitination and degradation of another adaptor protein IRS-1 (insulin receptor substrate 1) [42] . FGF-2 has been shown to up-regulate the expression of FIGC, a protein with intrinsic E3 ubiquitin ligase activity [43] , suggesting that FGF-2 may induce Nck uniquitination via FIGC. The present study showed that FGF-2-mediated ERK1/2 signalling interacted with ER stress signalling to control cancer cell life and death via proteasomedependent degradation of Nck in cancer cells. This information contributes to a better understanding of growth factor-mediated anti-apoptotic effects on ER stress. 
